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Abstract
Adipose tissue is composed mainly by adipocytes and stromal-vascular fraction, which 
are composed by different cell types including macrophages. There are three types of 
adipose tissue: brown (BrAT), white (WAT), and beige (BeAT). BrAT is less abundant and 
is implicated in lipid oxidation and energy balance; BeAT has the pathway of adaptive 
thermogenesis, and WAT is endocrine in nature and lipid storage site and is implicated as 
an endocrine organ that secretes hormones and different molecules. These molecules are 
pro-inflammatory and anti-inflammatory factors, including the adipokines leptin, adipo-
nectin, resistin, and visfatin, as well as cytokines and chemokines, such as tumor necrosis 
factor (TNF)-α, interleukin (IL)-6, leptin, adiponectin, and others, are involved with the 
development of adipose tissue inflammation and obesity. This pathological condition, 
together with other factors such as oxidative stress, may develop insulin resistance and 
the pathogenesis of type 2 diabetes mellitus (T2DM).
Keywords: adipose tissue, inflammation, oxidative stress, insulin resistance,  
type 2 diabetes mellitus
1. Introduction
Adipose tissue at first considered as a fat storage and insulation organ had a radical change 
when leptin, the hormone of obesity, was discovered [1]. Since then, the adipose tissue has 
gained more interest to know its role as an endocrine tissue and its capacity of producing 
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other molecules that have action in various parts of the body including metabolic regula-
tion and the immune system. Adipose tissue is composed primarily by pre-adipocytes and 
adipocytes, but other types of cells called the stromal-vascular fraction composed by differ-
ent cell types including macrophages, neutrophils, lymphocytes, fibroblast, and endothelial 
cells among others also are present [2]. The presence of these cells account for the vast secre-
tion of molecules called adipokines with various significant physiological functions, many of 
them implicated in metabolism and others implicated in the balance between pro- and anti-
inflammation to maintain the homeostasis. In obesity, there is a strong inflammatory response 
in adipose tissue, which is one of the most important causes for the development of insulin 
resistance and the pathogenesis of T2DM.
2. Morphology and physiology of adipose tissue
The adipose tissue originates from the mesenchymal cells and around the blood vessels in 
the 14th and 24th week of embryonic development. In the late stage, fibrous and vascular 
septa are formed between the aggregates of lipocytes that appear in the face, neck, breast, and 
abdominal wall at 14 weeks, and at 15 weeks, it is already evident in the back and the shoul-
der, later extending to limbs, higher and lower at 23 weeks. There is an excellent association 
between adipogenesis and angiogenesis, since lipoprotein-lipase accumulates in the lipocyte 
membrane, which transfers serum lipoproteins to lipocytes [3].
There are three types of adipose tissues: brown, white, and beige. They differ in development, 
anatomical location, and species. BrAT is less abundant and is implicated in lipid oxidation 
[2], and also has a great potential of impact on the energy balance. It is capable of rapidly pro-
ducing large quantities of heat through the activation of the only uncoupling protein (UCP)-1 
located in the mitochondria inner membrane. WAT is endocrine in nature and lipid storage 
site and is implicated as an endocrine organ that secretes hormones and different molecules 
as growth factors, complement factors, enzymes, and pro- and anti-inflammatory cytokines 
among others [2]; while BeAT is primarily white, it has some cells that have UCP-I. BrAT 
appears first in the fetus mid-gestation and is lost during the maturation of childhood, adoles-
cence, and mature age [4].
2.1. White adipose tissue
Histology: the preadipocyte is spindle-shaped with 4–5 cell extensions and abundant rough 
endoplasmic reticulum (ER). Adipocyte of WAT is a spherical cell with variable size from 10 to 
180 μm diameter depending of the content of the unique fat droplet (red arrow in Figure 1A) [5]; 
each fat cell is surrounded by its membrane, the center is occupied by a single-lipid vacuole, the 
cytoplasm is at the periphery as a rim, the nucleus is in flattened form and have a clear vacuole; in 
the rim of cytoplasm (arrowhead in Figure 1B), the tissue is subdivided into incomplete lobules 
by slim bands of collagen forming the stroma, in which there are several blood vessels (black 
arrow in Figure 1A), in the external membrane of endotelial cells of blood vessels are the lipo-
protein lipase to translate free fatty acids to adipocyte increasing like this the vacuole of lipid [4].
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The capacity of storing fat during excess food intake enables the organism to use this fat as energy 
source in starvation condition or in significant energy expenditure. However, as mentioned above, 
the adipocytes also produce and secrete different molecules. Some of them act as hormones or like-
hormones with actions related to the storage or utilization of fat, while other molecules produced 
by adipocytes play a role directly connected to the immune system in both innate and adaptive 
response. All these activities change the notion that adipocyte is merely a cell to store or release 
energy to a dynamic system of metabolic regulation as well as immune defense mechanism [6].
2.2. Brown adipose tissue
Histologically, BrAT is organized into lobules formed by fat cells surrounded by collagen 
bands mixed with capillaries, nerves, and connective tissues. In BrAT, in the cells, the lipid 
droplets accumulate in multiple vesicles and therefore appear as multivesicular (red arrow in 
Figure 2A) intermixed with abundant mitochondria, given to the cytoplasm a multigranular 
shape surrounding the prominent central nucleus (red arrow in Figure 2B). In some brown fat 
cells, the lipid gathers, then the droplets coalesce into a large vacuole that gives the cell first an 
oval and finally round shape as unilocular cell (asterisk in Figure 2A). The cells are polygonal 
in shape with a mixture of multivacuolated and univacuolated cells.
Brown adipose cells are surrounded by a network of collagen fibers that contain abundant 
minute sympathetic nerves and blood vessels. Non-myelinated axons terminate in fat cells, 
providing for a direct sympathetic regulation, and the vascularity is ample with numerous 
capillaries coursing between the adipocytes [4]. Brown adipose cells have numerous mito-
chondria that participate in heat production through UCP-1 protein. This protein is located 
in the inner mitochondrial membrane where it is responsible for uncoupling of adenosine-
5’-triphosphate (ATP) production to use the conductance of H+ gradient to produce heat [7].
Figure 1. Photomicrography of white adipose tissue. (A) Photomicrography of WAT-150 μm. The red arrow shows the 
unilocular fat cell, cytoplasm. The black shows blood vessel. (B) Photomicrography of WAT-15 μm. The red arrows show 
the nucleus. V: blood vessel. Toluidine blue stain in L.R. White resin.
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2.3. Beige adipose tissue
The BeAT is very similar histologically to BrAT; despite these similarities, it is now clear that 
the “classical” brown fat cells and the inducible “beige” fat cells come from different devel-
opmental lineages and are, in fact, distinct cell types; however, BeAT have the pathway of 
adaptive thermogenesis which is activated by cold via, and indirect pathway mediated by the 
sympathetic nervous system. Additionally, fat cells are also able to directly sense cold. The 
thermogenesis that is carried out in the Beige tissue is also by the UCP-1 protein. As men-
tioned above, this protein decouples the protons that would be used in the respiratory chain, 
thus transporting to heat producing in the inner membrane of the mitochondria instead of 
producing ATP; in this way, the chemical energy of the lipids and carbohydrates is released 
as heat and not by the formation of ATP [8].
This form of heat formation by adipocytes contributes to metabolic homeostasis, since the 
partial elimination of the UCP-1 protein in transgenic strains of mice is more susceptible to 
obesity and diabetes. Likewise, the total absence of the UCP-1 protein considerably increases 
the weight and fat content, which is demonstrated in the total absent mouse model of the 
forkhead box protein (FOX)-C2; these mice were induced to diabetes and obesity with consid-
erable increase in brown and beige fat [8].
2.4. Genetics
At birth, there is approximately 16% of adult fat, and it is proliferating until puberty; from 
this the fatty tissue does not increase in volume except in exceptional cases of overfeeding, or 
slightly decreases in cases of strict diets of food reduction. The differentiation of adipocytes is 
controlled by the CHOP gene, which encodes a protein CCAAT/enhancer protein (C/CEBP), 
which also controls the differentiation of fibroblasts to adipocytes [4].
Figure 2. Photomicrography of Brown adipose tissue. (A) Photomicrography of BrAT-150 μm. The red arrow shows the 
multilocular fat cell and nucleus. The asterisk shows an unilocular fat cell. (B) Photomicrography of BrAT-15 μm. Red 
arrow shows the nucleus. Toluidine blue stain in L.R. White resin.
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2.5. Physiology
White fat serves as a thermal insulator and protector of underlying tissues, and is essential in 
the uptake, synthesis, and storage of lipids and release of fatty acids in response to various 
neuronal and hormonal stimuli. This function is regulated by the hormone adipocyte lipopro-
tein lipase (LPL) which is increased in obesity and decreases with periods of lack of nutrition 
(starvation) and in diabetes. Insulin inhibits hormone-sensitive lipase and therefore blocks the 
release of fatty acids. It also serves to promote the uptake of glucose by adipocytes which 
are the precursor of glycerol phosphate, which in turn is necessary for the synthesis of tri-
glycerides. Adipocytes have alpha and beta-adrenergic receptors; B1 adrenoreceptor agonists 
stimulate lipolysis, while alpha2 inhibitors inhibit it, both work through the cAMP as the 
second messenger. There are bodily differences, in some women there is a predominance of 
alpha 2 receptors in fat tissue of the gluteal region; therefore, although they are thin in other 
parts of the body, this gluteal region does not undergo changes in the fat content; on the other 
hand, some other people have more LPL, and based on the above, we can see that different 
body regions have different amounts of LPL receptors and alpha and beta-adrenergic recep-
tors, which allow different deposits of fat in men and women. Growth hormone, insulin, 
glucocorticoids, and estradiol-17β stimulate the synthesis of DNA in adipocytes of both men 
and women [3].
3. Molecules secreted by adipocytes and stromal-vascular fraction
Although TNF-α, a potent pro-inflammatory cytokine [9, 10] was the first cytokine discovered 
that is secreted by adipose tissue [11], the leptin was the first molecule with hormonal activ-
ity that is secreted by adipocytes. Since then, multiple molecules called adipokines have been 
discovered as factors that are secreted by adipocytes or by the stromal-vascular fraction, com-
posed mainly by macrophages, neutrophils, lymphocytes, fibroblast, and endothelial cells. 
This knowledge gave evidence that the adipose tissue modules various parts of the body 
and it is now considered as an organ endocrine, paracrine, or autocrine secreting molecules 
with activities as hormones, grow factors, chemotactic molecule, enzymes, and pro- and anti-
inflammatory factors [12, 13].
3.1. Hormones
Adipocytes are cells metabolically dynamic that secrete multiple hormones that regulate the 
homeostasis. Leptin, acylation stimulating protein (ASP), adiponectin, resistin, and visfatin 
are hormones produced and secreted by adipocytes. These hormones play a key role over 
regulatory functions of various mechanisms such as beta-oxidation, fatty acid synthesis, and 
energy metabolism [14, 15]. Leptin is a hormone that suppresses food intake, and the gene that 
encodes this hormone is called obesity gene. Adiponectin is implicated in the metabolism of 
glucose and fatty acids. Acylation stimulating protein is concerned with fat-store. Resistin is a 
hormone implicated in resistance of insulin, and visfatin is a hormone with implication in the 
utilization of glucose. However, these hormones also are implicated in inflammation process 
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and they can interact with cells of the innate and adaptive immune system modulating the 
production of cytokines from adipocytes and the stromal-vascular fraction [16, 17] (Figure 3).
3.2. Growth factors
Fibroblast growth factors (FGFs), insulin-like growth factor (IGF)-1, hepatocyte growth factor 
(HGF), nerve growth factor (NGF), vascular endothelial cell growth factor (VEGF), and trans-
forming growth factor (TGF)-β are growth factors that also can be produced by adipose tissue, 
and they can induce the adipogenesis [18], glucose metabolism [19], angiogenesis [20, 21] and 
thermogenesis [22]. However, they can also be implicated in inflammation processes (Figure 3).
3.3. Cytokines
There are many cytokines implicated in inflammation and there are differences in cytokine 
type according the individual status. The cytokines can be classified as pro-inflammatory 
or anti-inflammatory, although depending on the condition, some cytokines overlap both 
pro- and anti-inflammatory function. Also, depending on the condition of the body diverse 
Figure 3. Adipokines secreted by adipose tissue linked to metabolic regulation and immune response. CCL, 
CC-chemokine ligand; CXCL, CXC-chemokine ligand; IL, interleukin; IL1-RA, interleukin-1-receptor antagonist; NGF, 
nerve growth factor; PAI-1, plasminogen activator inhibitor 1; TNF, tumor necrosis factor; VEGF, vascular endothelial 
growth factor. Description in the text.
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types, cytokines can be produced; for example, in lean condition, IL-10, IL-4, IL-13, and IL-1 
receptor antagonist (IL-Ra) are commonly produced and these cytokines exert anti-inflam-
matory function. On the contrary, obese individuals mainly produce and secrete IL-1, TNF-α, 
and IL-6 implicated in the inflammatory process [23, 24]. Although there are other cytokines 
produced by the adipocytes as Leukemia inhibitory factor, interferon (INF)-α, IL-6, and 
transforming growth factor (TGF)-β that can function as both pro-inflammatory and anti-
inflammatory cytokines [25].
4. Relationship among adipokines and immune system
The relationship among adipokines with the immune response is complex. In addition to adi-
pocytes, other cells are necessary in adipose tissue to exert its function. Cells like macrophages 
and lymphocytes can infiltrate the adipose tissue. There is a difference over the presence of 
these cells among individuals and the cell number is proportional to the size of the adipocytes. 
There is more infiltration of macrophages and lymphocytes in obese individual than normal 
individuals. Even more, there is a significant difference considering the base line number of 
these cells in normal individuals compared with the number observed in starvation and obese 
individuals [26, 27].
In the last 25 years, the relationship between adipose tissue and immune response has been 
extensively studied. The innate response with the production of pro-inflammatory cytokines is 
the main activity detected in adipocytes in normal condition. Macrophages are the main cell in 
adipose tissue that produces the first adipokines linking the innate and adaptive response. In 
normal condition, there is a homeostasis with different number of cytokines produced by mac-
rophages mainly anti-inflammatory factors. In lean condition, macrophage population consist 
of M2 phenotype producing anti-inflammatory cytokine, whereas in obese condition, the macro-
phages are classically activated producing pro-inflammatory cytokine with increasing levels of 
TNF-α that exert multiples effects in different cells population around the body (Figure 4) [28].
The macrophages in adipose tissue have two origins. First, there is evidence that there exists 
a macrophage resident population established since embryonic development [29], and other 
population are monocyte-derived macrophages that respond to the inflammation process [30]. 
However, the population of macrophages that respond in the inflammation process is origi-
nated from circulating monocytes. In this initial process of inflammation, death adipocytes are 
capable to attract macrophages and depending of the type of cell death is the type of cytokine 
produced: apoptotic cells establish the production of anti-inflammatory cytokine, whereas 
necrotic cell establish a pro-inflammatory cytokine production characterized by the secretion 
of IL-1 from the macrophages population [31, 32]. Also, exogenous or endogen fatty acid as 
well as exogenous lipopolysaccharide are capable of inducing inflammation in adipose tis-
sue through the activation of toll-like receptors present in both adipocytes and macrophages. 
However, the factors produced by the adipose tissue, both hormones and cytokines, have 
effect over other cell types including lymphocytes, dendritic cells, and neutrophils among 
others, affecting different mechanisms related with the production and release of multiple 
cytokines of the innate and adaptive response [16, 17, 33] (Figure 4). Now, the functionality 
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of the adipose tissue under obesity condition have gained considerable interest mainly by its 
relationship with different diseases including diabetes, cardiovascular disease, metabolic syn-
drome, and its possible association with joint diseases [34, 35].
5. Relationship of obesity with inflammation, oxidative stress, 
insulin resistance, and type 2 diabetes mellitus
5.1. Obesity
Obesity is a medical condition with a major negative impact on health, mainly caused by a 
series of environmental, humoral, and genetic factors. Within these environmental factors such 
as the decrease in physical activity, sedentary lifestyle, and increase in foods with a high index 
[36], this produces a positive energy balance and this excess energy is stored in the form of 
fat that accumulates in the adipocyte and other organs such as the muscle and liver; how-
ever, some individuals are exposed to these factors and do not become obese, suggesting that 
genetic factors load may predispose individuals to develop obesity [37]. There are genes that 
have a high capacity to induce a state of obesity. Among them are those that regulate the intake 
and satiety, such as the gene of leptin or its receptor, alterations in the proopiomelanocortin 
Figure 4. Adipokines and innate and adaptive response. Factors secreted by adipose tissue modulate various 
immunological process including activation and inactivation of leucocytes, and cell apoptosis, linking the innate and 
adaptive response. COX-2, cyclo-oxygenase 2; HMW, high molecular weight; IgG, immunoglobulin G; IFN, interferon; 
IL, interleukin; LTB-4, leukotriene B4; NFκB, nuclear factor κB; NOS, nitric oxide synthase; TCR, T-cell receptor; Th, 
helper T cell; TNF, tumor necrosis factor; TREG, regulatory T cell. Description in the text.
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gene or in the melanocortin-4 receptor, mutations in some of these genes can cause the obesity 
[38]. On the other hand, investigations of recent years suggest the participation of inflamma-
tory pathways and increased levels of pro-inflammatory cytokines, such as the nuclear factor 
(NF)-κB resulting in an increase of the IL-6, TNF-α, and IL-1β [39], with the development of 
obesity and obesity-associated insulin resistance, since inflammation caused a significant dete-
rioration in the signaling pathways of insulin and leptin [39–42].
5.2. Inflammation
Inflammation is a process of activation of innate immune system, in response to exogenous and 
endogenous factors, such as infection by microorganisms, tissue stress, and injury [43]. The 
inflammatory response is characterized by its cardinal signs, such as redness, swelling, heat, 
pain, and interrupted function [44]. The inflammatory response consists of four main compo-
nents: (1) endogenous or exogenous factors, such as molecular patterns associated with patho-
gens (PAMP) and damages (DAMP), which are derived from bacteria, viruses, fungi, parasites, 
and cell damage, as well as toxic cellular components or any other harmful condition [45]; (2) 
cellular receptors that recognize these molecular patterns (PRR), including Toll-like receptors 
(TLRs), nucleotide binding oligomerization domain (NOD)-like receptors (NLR), and retinoic 
acid inducible gene (RIG)-like receptors [46, 47]; (3) pro-inflammatory mediators, such as cyto-
kines, chemokines, and the complement system [48]; (4) target cells and tissues, where these 
pro-inflammatory mediators act. The inflammatory response is characterized mainly by four 
successive phases: (1) silent phase, where the cells synthesize and release the first pro-inflam-
matory mediators, (2) vascular phase, characterized by increased vascular permeability and 
dilatation, (3) phase cellular, which is characterized by the infiltration of inflammatory cells to 
the site of damage, and (4) resolution of the inflammatory response [49–52].
Adipocytes and macrophages of the stromal fraction of adipose tissue express elevated levels 
of PRRs in response to various stimuli. The activation of PRRs activates a signaling cascade 
through canonical adapters of receptors, for example, the activation of TLRs that activates 
myeloid differentiation primary response (MYD)-88 located in plasmatic membrane or in 
endosomes associated with Toll IL-1r (TIR). This interaction activates a family of kinases 
which in turn activate different molecules including NFκB, a primary transcription factor. The 
translocation of NFκB to the nucleus upregulates the production of INF and inflammatory 
cytokines, which is an evidence that these receptors play a role in the immune system [53, 54].
5.3. Inflammation and obesity
The alteration of the metabolic syndrome as a consequence of obesity is one of the most com-
mon factors that evoke the activation of inflammation, producing other alterations such as 
oxidation, cellular hypertrophy, and stress, among others [55].
The metabolic and immune systems are regulated among themselves, and are made up of 
hormones, cytokines, signaling proteins, transcription factors, and bioactive lipids. The basic 
inflammatory response therefore promotes a catabolic state and suppresses anabolic path-
ways, such as the highly conserved and potent insulin signaling pathway [55, 56].
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The inflammation attributed to obesity is given by the excessive intake of fats, macro nutri-
ents, and foods rich in antioxidants causing deposition in other organs, mainly in the liver, 
altering insulin levels. There are other conditions due to obesity, such as alterations in blood 
pressure, heart rate, respiratory rate, and psychological factors [56, 57].
Obesity causes the increase and the extension of adipose tissue, and molecularly induces 
the release of signals and protein mediators called adipokines. The inflammatory response 
is derived from the high production of adipokines that produce the release of inflammatory 
mediators such as leptin, adiponectin, TNF-α, IL-1β, IL-6, protein monocyte chemotactic 
(MCP)-1, macrophage migration inhibitory factor (MIF), NGF, VEGF, plasminogen activator 
inhibitor (PAI)-1, and haptoglobin [39]. Several studies have shown the expression of these 
pro-inflammatory mediators (mainly TNF-α and IL-1β) in metabolic alterations [40].
The increase of evidence in studies of human population and research in animals has estab-
lished causal links of diseases such as insulin resistance, T2DM, and metabolic syndrome as a 
result of the increase of adipocytes [40].
A study by Haiyan Xu et al. demonstrated the active role of macrophages in morbid obesity 
and the relationship they have with inflammatory processes, concluding that a disease of 
chronic inflammation initiated in adipose tissue is a consequence of insulin resistance [58, 59]. 
While it is clear that the inhibition of insulin receptor signaling pathways is a central mecha-
nism by which inflammatory and stress responses mediate insulin resistance, it is likely that 
other pathways, molecules, and proteins have not been discovered yet with an alternative 
mechanism involved in this interaction [59, 60].
Recent research shows that the main risk to develop a metabolic complication is insulin resis-
tance. However, in addition to cardiovascular and hematological diseases, pathologies such 
as fatty liver, airway diseases, cancer among other diseases that increase lipid or cytokine 
levels and, in turn, develop insulin resistance in the absence of obesity are related [61].
It is important to understand the inflammatory pathogenic mechanisms that produce diseases 
in the absence or presence of obesity. The aim is to reduce the rate of morbidity and mortality 
by preventing and treating pathologies that link inflammation with obesity [40].
5.4. Oxidative stress and obesity
Previous studies have reported and suggested that obesity and oxidative stress have rela-
tionship. Some markers of oxidative stress such as malondialdehyde (MDA) are increased in 
obese people by the production of reactive oxygen species (ROS) and for decrease in activity 
of antioxidant enzymes such as serum superoxide dismutase (SOD) and catalase (CAT). These 
factors are involved in the development of oxidation, cell damage, and metabolic diseases [62]. 
However, other studies suggest that obesity per se can induce systemic oxidative stress through 
multiple biochemical mechanisms, such as the generation of superoxide, nicotinamide ade-
nine dinucleotide phosphate (NADPH) oxidase, oxidative phosphorylation, glyceraldehyde 
autoxidation, activation of protein kinase (PK)-C and pathways of hexosamine and polyol. 
On the other hand, studies suggest that obesity may be caused by oxidative stress through the 
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proliferation of preadipocytes and increased size of differentiated adipocytes [63–65]. Obesity 
is an important risk factor for the development of metabolic syndrome (MetS), diabetes mellitus, 
dyslipidemia, atherosclerosis, hypertension, insulin resistance, hepatic steatosis, non-alcoholic 
liver disease, and high morbidity and mortality [66] (Figure 5).
Several investigations and different clinical disciplines in recent years have focused their interest 
on oxidative stress. This evidence is associated with the pathogenesis of different diseases among 
which are diabetes, obesity, cancer, aging, inflammation, neurodegenerative disorders, hyperten-
sion, apoptosis, cardiovascular diseases, and heart failure [67], and is considered responsible 
for the beginning and progression of sundry brain disorders that include major depressive dis-
order [68]. From these investigations appears the concept that oxidative stress is the “common 
final pathway” through, whereby diseases produce their harmful effects. Oxidative stress causes 
complex alterations of cell metabolism and cell–cell homeostasis, in particular, oxidative stress is 
the key in the pathogenesis of insulin resistance and B cell dysfunction as well as in obesity [67].
Janus gas, oxygen (O2), has positive beneficial effects as side effects injurious for biological systems. Its reactivity allows oxygen to participate in the transfer of high-energy electrons 
and therefore generates large amounts of ATP through oxidative phosphorylation. Just as 
oxygen is essential for life [66] and necessary to allow the evolution of multicellular organ-
isms, it is also capable of attacking any biological macromolecule and the protein, lipid, or 
deoxyribonucleic acid (DNA) [66, 69], provoking diseases through an uncontrolled produc-
tion of oxygen free radicals (RLO) and attacking cellular processes (enzymes production and 
cellular respiration) [66]. These events cause our body subdued to a constant oxidative attack 
of ROS [69]. Oxidation is the process that is held by the loss of electrons, which is always 
Figure 5. Factors contributing to increased oxidative stress (OS) in adipocytes and linked to insulin resistance, 
inflammation of adipose tissue, and decreased adiponectin. TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; 
MCP-1, monocyte chemoattractant protein 1. Description in the text.
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associated with another catchment (reduction). This oxidation is essential for life and partici-
pates in processes of obtaining cellular energy [66]. The damage produced by the imbalance 
between oxidants and antioxidants in favor of oxidants is called “oxidative stress.” Oxidants 
are formed as a normal product of aerobic metabolism, but its production increases rapidly 
under pathophysiological conditions [70].
Oxidative stress can be defined as the appearance of macromolecular damage from free rad-
icals and thiol alterations that lead to redox control dysfunction [71], where the excess of 
endogenous oxidative species can damage the cells and manipulate the signaling pathways. 
Oxidative stress agents that occur at low physiological levels in mitochondria and peroxi-
somes are: reactive species, ROS such as superoxide, hydrogen, peroxide, and hydroxyl ion 
radicals. The endogenous ROS that occur at low levels are physiologically important, espe-
cially in signaling pathways, although these mechanisms are not yet clear because they per-
form a double function both as a signal and as a damaging agent. Among these signaling roles 
are transcriptional control and cell cycle regulation. Oxidative stress occurs when free radical 
species such as ROS and reactive nitrogen species exceed the capacity of cells to eliminate 
them through their antioxidant defense mechanisms, which have multiple nocuous effects on 
the cellular metabolism [65, 72]. It has long been accepted that ROS becomes harmful to cells 
even at low physiological levels. Recent studies have concluded that ROS damage has a direct 
role in the development and progression of many chronic diseases, including the pathogen-
esis of insulin resistance and T2DM [73].
Several studies have reported that obesity is associated with oxidative stress caused by an 
imbalance related to inadequate antioxidant defenses and an increase in the proportion of 
free radical formation [65, 74]. However, other studies suggest that obesity per se can induce 
systemic oxidative stress through multiple biochemical mechanisms, such as the generation 
of superoxide NADPH oxidase, oxidative phosphorylation, glyceraldehyde autoxidation, 
activation of PKC, and pathways of hexosamine and polyol. Hyperleptinemia, tissue dysfunc-
tion, low antioxidant defenses, chronic inflammation, and the generation of postprandial ROS 
are factors involved in the development of obesity in which oxidative stress participates [75] 
(Figure 5). As the increase in oxidative stress in accumulated fat is, at least in part, the under-
lying cause of adipocytokine dysregulation and the development of the metabolic syndrome 
[76], it is known that obesity induces oxidative stress through various mechanisms such as 
chronic inflammation, endothelial dysfunction, and mitochondrial dysfunction [77].
In vitro and in vivo studies suggest that obesity may be caused by oxidative stress through the 
proliferation of preadipocytes and increased size of differentiated adipocytes [63, 64]. The mass of 
adipose tissue increases when the pre-adipocytes differentiated in the terminal phase re-enter the 
cell cycle and undergo proliferation, process called adipogenesis, which includes the proliferation 
of preadipocytes and their differentiation into mature adipocytes [64]. It has been shown that ROS 
are implicated in both events. The proliferation of pre-adipocytes activated by ROS participates 
in the development of metabolic disorders, which generate more ROS through mechanisms that 
include chronic inflammation of adipocytes, oxidation of fatty acids, excessive oxygen consump-
tion, and accumulation of cell damage, diet, and mitochondrial activity [64, 78]. Abnormal gen-
eration of ROS induces cellular dysregulation in many other tissues and promotes obesity [65].
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The generation of ROS by the accumulation of adipocytes through the activation of NADPH 
oxidase produces dysregulation of the expression of inflammatory adipocytokines that include 
adiponectin, PAI-1, IL-6, and MCP-1 and decrease in the production of antioxidant enzymes 
[71] (Figure 5). Some biomarkers that are known for oxidative stress in serum and urine 
plasma are: MDA, isoprostanes F-2 (F2-IsoP), Prostaglandin F2a 8-iso (8-isoPGF2a), and car-
bonylation proteins. A significant positive correlation has been observed between the corporal 
mass index (BMI) and the biomarkers of oxidative stress [79]. Lower activity of antioxidant 
enzymes Cu-Zn superoxide dismutase (SOD) [75], Cat [62], and glutathione peroxidase (GPx) 
has been reported in erythrocytes of obese subjects than in non-obese controls [75, 80, 81].
Obesity is an important risk factor for the development of MetS, diabetes mellitus, dyslipid-
emia, atherosclerosis, hypertension, insulin resistance, hepatic steatosis, non-alcoholic liver 
disease, and high morbidity and mortality. Sundry mechanisms may be involved in the devel-
opment of comorbidity related to obesity, including the abnormal production of adipocyto-
kines, aberrant oxidative stress, and dysregulated pro-inflammatory response in tissues such 
as muscle and liver. It has been reported that both obesity and oxidative stress can occur 
in the first two decades of life [82] and accumulated fat is considered an early indicator of 
the metabolic syndrome associated with obesity which is related to a multitude of different 
diseases [74]. Therefore, when there is an excess in oxidation, oxidative stress appears which 
becomes complex at all biological levels since it is not possible to measure it or define it with a 
single parameter [67]. For all the above reasons, the development of new therapies should be 
considered as a major objective [76] for the treatment and control of oxidative stress in obesity 
as well as for diseases in which oxidative stress is involved.
5.5. Insulin resistance and obesity
Insulin exerts its effect through binding to its receptor; the insulin receptor (IR) has two iso-
forms: IR-A and IR-B. IR-A is found mainly in the adult nervous system and has a much 
higher affinity for insulin than IR-B, and this latter is mainly found in adipose tissue, liver 
tissue, and skeletal muscle [83]. This receptor is constituted by two α- and two β-subunits 
with a molecular weight of 350 kDa. The α-subunits are located on the outside of the plasma 
membrane and contain insulin-binding sites, while the β-subunits have a transmembrane, 
a juxtamembrane and an intracellular domain, where tyrosine kinase activity is found [84].
Under normal conditions, insulin binds to the α-subunit of the IR and promotes the autophos-
phorylation of the tyrosine residues of the β-subunit of the receptor. Then, there is a transphos-
phorylation that is recognized by some adapter molecules, among them are the insulin receptor 
substrates (IRS), that there are three types and are expressed in humans. IRS-1 and IRS-2 are 
widely distributed in mammalian tissue, while IRS-4 restricts its expression to the hypothala-
mus [85], these proteins are adapter molecules for the kinase activity of the phosphorylated 
insulin receptor, in turn phosphorylating the p85 regulatory subunit of phosphoinositide 
3-kinase (PI3K). The phosphorylation of the latter induces a conformational change of this pro-
tein which leads to the binding of the catalytic subunit (p110) activating PI3K; once activated, 
this protein phosphorylates phosphatidylinositol-3,4-diphosphate (PIP2) into the second mes-
senger phosphatidylinositol-3,4,5-triphosphate (PIP3) [86, 87], and these lipid products induce 
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the recruitment and the interaction of the protein kinase (PDK)-1 and serine/threonine-specific 
protein kinase (Akt). The activation of PDK-1 phosphorylates some isoforms of protein kinase 
C, such as PKCλ/ζ, which is responsible for phosphorylating vesicles that contain the glu-
cose transporter type 4 (GLUT4), promoting migration and fusion with the cell surface, which 
increases glucose uptake as well as your metabolism [88] (Figure 6A).
As we know, glucose is the main source of energy used by the organism and the only source 
of energy for the brain. Thus, glucose homeostasis must be finely regulated, and blood glu-
cose levels must be kept within a very defined range (70–90 mg/dL). When the organism pres-
ents obesity, this regulation can be altered together with other factors, then insulin resistance 
(IR) appears [89]. This alteration is defined as a pathological state where there is a decrease 
in the metabolic response of target cells, tissue, or the whole organism to the action of insu-
lin. Although acute hyperinsulinemia can be tolerated, chronic hyperinsulinemia exacerbates 
insulin resistance in different tissues and contributes to the failure of β cells to produce insulin 
and ultimately diabetes is established [90]. Insulin resistance is characterized by a series of 
alterations at the intracellular level, such as a decrease in the concentration of the receptor and 
its kinase activity, the concentration and phosphorylation of IRS-1 and IRS-2, PI3K activity, 
translocation to the membrane of the GLUT4 and the activity of intracellular enzymes [91]. 
Insulin resistance has been associated mainly with a state of obesity and physical inactivity, as 
well as a genetic predisposition, the stress on the β cells, causing an alteration in the function 
of these cells and a progressive decrease in the secretion of insulin [92]. IR can be divided into 
two types: hepatic IR or peripheral RI. Hepatic RI is an altered state of the synthesis of glucose 
in the liver, while peripheral RI is the reduced response of the skeletal muscle or adipose tis-
sue to the action of insulin [93]. In the muscle, the alterations that contribute to develop RI can 
be mentioned as defects in: the insulin signaling, in the glucose transporter, in the phosphory-
lation of glucose, in the synthesis of glycogen, in the activity of the pyruvate dehydrogenase 
complex and in mitochondrial oxidative activity [94].
On the other hand, hepatic IR increases gluconeogenesis since some substrates (fatty acids, 
lactate, glycerol and amino acids) are derived from a deficiency of insulin signaling, hyperglu-
cagonemia, and increased sensitivity to glucagon, which leads to increased gluconeogenesis; 
this overproduction of glucose by the liver occurs in the presence of increased levels of insulin, 
indicating resistance to insulin-induced suppression of hepatic glucose. This increase may 
have other factors that contribute to accelerate this production: increased glucagon levels and 
an increase in liver sensitivity to glucagon; lipotoxicity that induces an increase in the expres-
sion and activity of the enzymes phosphoenolpyruvate carboxykinase and pyruvate carbox-
ylase; glucotoxicity that increases the expression and activity of glucose-6-phosphatase [95].
With the development of IR, the β cells of the pancreas increase the production and secre-
tion of insulin as a compensatory mechanism (hyperinsulinemia) and the insulin receptor 
is insensitive to the action of this hormone, increasing the biochemical levels in blood as, 
glucose, triglycerides, and cholesterol, and lowering high density lipoprotein (HDL) choles-
terol; this imbalance contributes to the development of cardiovascular diseases and metabolic 
syndrome [96]. The prolonged elevation of insulin at systemic level can lead to dysfunction in 
the signaling of the insulin receptor, mainly of the skeletal muscle, since when it is in a state of 
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insulin resistance, the synthesis of glycogen is altered due to the decrease in glucose uptake. 
Insulin loses its ability to lower glucose levels through the transcription factor FOXO1 in the 
liver because the hormone loses its ability to inhibit this factor, which is involved in regulat-
ing gluconeogenesis enzymes. On the other hand, the disruption in the translocation of the 
GLUT4 glucose transporter from the cytoplasm to the membrane decreases its expression on 
the membrane, which results in a reduced uptake of circulating glucose.
Insulin resistance is associated with the phosphorylation of the IRS, since there is an increase 
in phosphorylation in the serine and tyrosine residues (serine/threonine) of this protein, 
which causes phosphorylation decrease and reduction in the interaction with the PI3K and 
the Akt, thus decreasing its activity. There is also evidence that adipose tissue plays an impor-
tant role in the development of insulin resistance, and this tissue can regulate the metabolism 
of glucose in the body, through the regulation of free fatty acids, the secretion of adipokines, 
since it acts as an endocrine organ [97]. The ectopic accumulation of lipids in muscle and liver 
induces insulin resistance through the increase in the levels of diacylglycerol (DAG), and its 
accumulation promotes the translocation and activation of the protein kinase (PK)-C in the 
tissues, the PKC-θ in the muscle, and in the liver the PKC-δ and PKC-ε, which are involved in 
inhibiting the kinase activity of the receptor to insulin and thus inhibit insulin signaling [92]. 
The phosphorylation of IRS-1 at the residue of Serine-1101 by PKC-θ showed a blockade of 
the insulin-stimulated IRS-1 tyrosine phosphorylation [98]; this determines the signaling of 
insulin (Figure 6B). In addition to DAG, another fatty intermediate that is involved in insu-
lin resistance is ceramides that can act as a second messenger and can modulate the activity 
Figure 6. Insulin signaling in normal and obesity conditions. (A) Insulin signaling and glucose production under normal 
conditions. (B) Insulin resistance and obesity. IR, insulin receptor; IRS, insulin receptor substrates; PI3K, phosphoinositide 
3-kinase; PIP2, phosphatidylinositol-3,4-diphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate; PDK-1, protein 
kinase 1; Akt, serine/threonine-specific protein kinase; GLUT4, glucose transporter type 4; FFA, free fatty acids; 
DAG, diacylglycerol; PKC, protein kinase C; JNK, C-Jun N-terminal kinases; TLR4, Toll-like receptor 4. Description 
in the text.
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of kinases, phosphatases, and some transcription factors. These ceramides reduce the phos-
phorylation of IRS-1 through insulin and, in turn, are involved in the activation of protein 
phosphatase (PP)-A2, which can inhibit the phosphorylation of the Akt2 protein in muscle, 
which influences glucose consumption, since it inhibits the translocation of the GLUT4 glu-
cose transporter to the plasma membrane [99].
Ceramides also activate inflammatory pathways such as c-Jun N-terminal kinases (JNK) and 
transcription factor NF-κB. The activity of JNK has been related to the pathogenesis of insulin 
resistance by the phosphorylation of IRS-1 in the Serine-307 residue; when this phosphoryla-
tion occurs, the activity in the signaling of the ISR-1 is diminished [100]. Phosphorylation of 
serine residues has been associated with blocking IRS-1 and inhibiting IR/IRS interaction, 
thus promoting the degradation of the IRS-1 protein, and thus inducing a lack of insulin 
response, which generates an insulin resistance.
On the other hand, obesity has been associated with low-grade inflammation, where insulin 
signaling in the adipocyte and hepatocyte is inhibited through several mechanisms, one of 
which is the inhibition of IRS-1 and the signaling cascade of insulin. Another mechanism 
is the inhibition of peroxisome proliferator-activated receptor (PPAR)-γ function; this is a 
nuclear factor that activates lipid synthesis through inducing enzymes and proteins involved 
in lipogenesis and fat storage, so that inhibition contributes to insulin resistance [101]. The 
increase of free fatty acids involve another mechanism where these acids activate some recep-
tors involved in the innate immune response; among these are the TLRs, the medium chain 
fatty acids that can activate the TLR4 and this in turn initiates the intracellular signaling cas-
cade that culminates in the activation of NF-κB, JNK, and suppressors of cytokine signal-
ing (SOCS) pathways, involved in the activation of inflammatory pathways that induce the 
expression of inflammatory molecules including cytokines, chemokines, and effectors of the 
innate immune response; these molecules contribute to insulin resistance associated with obe-
sity [61, 99].
In a stage of obesity, macrophages infiltrate adipose tissue and are characterized by an increase 
in the number of pro-inflammatory M1 macrophages, as well as T helper 1 (Th1), Th17, and 
CD8+ T lymphocytes. The CD8+ cells play an important role in the differentiation, activation, 
and migration of macrophages, while TCD4+ lymphocytes and regulatory T cells are dimin-
ished [102]. Macrophages that infiltrate adipose tissue stimulate lipolysis and gluconeogen-
esis is stimulated through IL-6, thus causing hepatic insulin resistance. The adverse effects of 
inflammatory cells and mediators on adipocytes is to accelerate the transfer of lipids found in 
adipose tissue to tissues such as skeletal muscle and liver, which lead to ectopic lipid deposits 
leading to resistance to the insulin in these tissues causing a metabolic dysfunction [103].
5.6. Type 2 diabetes mellitus and obesity
Currently, it is estimated that approximately 415 million people have diabetes, of which more than 
90% have T2MD. However, 318 million people have a preclinical state of impaired glucose regula-
tion [104, 105], but intensive pharmacotherapy modifies the patient’s lifestyle, since it can reverse 
or delay the development of T2DM [106, 107]. In humans, obesity is the most common cause for 
developing insulin resistance, which is a key component in the etiology of T2DM [108, 109].
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T2DM has been considered as a metabolic disease. However, investigations of recent years 
have revealed that the inflammatory responses triggered by the production and the release 
of adipokines from WAT [110], as well as oxidative stress, are the most important factors 
related to the development of insulin resistance and the pathogenesis of T2DM [111]. Several 
investigations [112–116] have reported that the levels of the pro-inflammatory cytokines 
increase abnormally in both experimental animal models and patients with insulin-resistant 
and T2DM compared with normal controls, which demonstrates the role of pro-inflam-
matory cytokines in the development of insulin resistance and the pathogenesis of T2DM 
[117, 118]. Among the various pro-inflammatory cytokines, TNF-α is one of the most impor-
tant pro-inflammatory mediators that is critically involved in the development of insulin 
resistance and the pathogenesis of T2DM [111, 119]. The elevated level of TNF-α from tis-
sue macrophages [120] induces insulin resistance in adipocytes and peripheral tissues by 
altering insulin signaling through serine phosphorylation that leads to the development of 
T2DM [119].
On the other hand, recently, epigenetic factors have been implicated in the regulation of genes 
that are involved in the development of obesity; these factors are: changes in DNA methyla-
tion and microRNAs (miRNAs) expression non-coding miRNAs. Although multiple risk fac-
tors have been related to the development of obesity, however, it has not yet been determined 
how these factors interact with each other in order to develop this disease [121].
miRNAs are a family of small non-coding endogenous RNA molecules approximately 17 to 25 
nucleotides in length, which function as epigenetic regulators, modulating gene expression at 
the post-transcriptional level, without altering the DNA sequence. The miRNAs promotes the 
association of a protein complex, called the RNA-induced silencing complex (RISC), which 
directs the miRNAs to their target mRNA. The miRNAs generally bind to the 3′ untranslated 
region (UTR) of target mRNAs, through base pairing between a small fraction of the miRNA 
sequence, called the “seed” region composed of 2–7 nucleotides, to decrease gene expression 
by either of the two post-transcriptional mechanisms: translational repression or rapid degra-
dation of mRNA [122, 123].
Apart from their endogenous actions, miRNAs can be secreted into the extracellular space 
inside nanoparticles called Exos [124, 125]. These Exos contain numerous miRNAs, which can 
function locally or can enter the circulation to act in different sites. In addition, these Exos can 
be incorporated into other cells to modulate their function [126, 127].
Finally, a recent study reported that adipose tissue macrophages (ATM) of obese animals 
secrete Exos that contains miRNAs, which can be absorbed in insulin target cells, both in vitro 
and in vivo models, resulting in cellular and systemic insulin resistance, as well as intolerance 
to glucose. In contrast, the treatment of obese recipients with ATM-Exos derived from lean 
mice leads to an improvement in glucose tolerance and insulin sensitivity, both in vivo and 
in vitro. This study demonstrated that miR-155 is among the differentially expressed miRNAs 
in obese ATM-Exos, and that this miR-155 can inhibit insulin signaling and glucose tolerance 
[128], probably through a mechanism related to the suppression of its target gene peroxisome 
proliferator-activated receptor (PPAR)-γ [129], since when PPAR-γ is stimulated, it causes 
insulin sensitivity; whereas if it is inhibited, it causes insulin resistance [130] (Figure 7).




It is very important to understand that adipose tissue is not only a fat storage and insulation 
organ, but it is an endocrine tissue capable of producing a great variety of molecules, which is 
associated with other cells and has a close and complex relationship with the immune system. 
The imbalance in homeostasis, hyperplasia, and overproduction of adipokines leads to patho-
logical conditions, such as obesity and adipose tissue inflammation that can develop insulin 
resistance and favor the pathogenesis of T2DM.
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